Why our #biotech and #pharma clients turn into OmicsChart's champions🏆 ? Because we make sure that our results serve our clients long after handover.

Many providers treat #bioinfomatics project deliverables as the end goal. But the project doesn't end when service provision does. The true deliverable of a #bioinformatics consulting is not a table, a graph or a report, but a perspective that can be used to drive decisions 🎯

#biomarkers #oncology #immunooncology #rwe #rwd

'In this Review, we present current knowledge on the role of MDSCs in the immunotherapy of melanoma. We describe the accumulation, infiltration, and immunosuppressive functions of MDSCs in the tumor microenvironment (TME) as well as existing therapeutic strategies to target them in melanoma-bearing hosts. A special focus is placed on preclinical studies and clinical trials applying MDSC inhibition to overcome resistance to ICIs.'

#immunology #immunotherapy #immunooncology

https://www.jci.org/articles/view/170762

'Our current study detects chronic low-level type I interferon (IFN) activation in the cancer cells and the reciprocal astrocytes throughout the brain metastatic process. IFN responses in astrocytes promote brain metastasis by enhancing the recruitment of monocytic myeloid cells in both breast cancer and melanoma models'
#Immunology #immunotherapy #immunooncology

https://www.nature.com/articles/s41467-023-38252-8

This is not good.

"Changes to the primary end point during or after recruitment were omnipresent in randomized clinical trials with immune checkpoint inhibitors for patients with UC, RCC, and NSCLC. Most common were switching to or adding OS as an outcome measure and subpopulations based on PD-L1 expression. Ultimately, published data often do not allow readers to infer what the results would have been if the primary outcome had not been changed."

#Immunology #Immunotherapy #immunooncology #checkpointinhibitors

https://jamanetwork.com/journals/jamaoncology/fullarticle/2805960?guestAccessKey=c026475f-ec3b-48fb-886a-41ab2e638826&utm_source=linkedin_company&utm_medium=social_jamaonc&utm_term=10276892794&utm_campaign=article_alert&linkId=218897512

'In patients with resectable stage IIIA or IIIB NSCLC, perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a pathological complete response and longer survival than chemotherapy alone.'
#immunotherapy #Immunology #immunooncology #LungCancer

https://www.nejm.org/doi/full/10.1056/NEJMoa2215530

'To identify tumor-intrinsic drivers of resistance, we quantified in-vitro response to CD19-directed chimeric antigen receptor T-cells (CD19-CAR) and bispecific antibodies (BsAb) across 46 B-NHL cell lines and measured their proteomic profiles at baseline. Among the proteins associated with poor in-vitro response was Serpin B9, an endogenous granzyme B inhibitor.'

#CART #immunotherapy #Immunology #immunooncology #Preprint

https://www.biorxiv.org/content/10.1101/2023.06.26.546507v1?med=mas

"In this Review, we will discuss how CD8+ T cell developmental trajectories converge with tissue biology, and how factors such as migration to, localization within and the ability to sense different types of microenvironments shape T cell responses."

#Immunology #immunotherapy #immunooncology

https://www.nature.com/articles/s41577-023-00884-8

Yet another study showing that tumor mutation burden is a poor predictor of response to checkpoint blockade.

"First we assembled the largest pan-cancer dataset of immunotherapy patients with sequencing and clinical data. Surprisingly, we find little evidence that TMB is predictive of response to ICB.
(...)
Our analysis shows that the use of TMB in clinical practice is not supported by available data and can deprive patients of treatment to which they are likely to respond."
#Immunology #immunooncology #immunotherapy

https://elifesciences.org/reviewed-preprints/87465

Cholesterol & anti tumor T cell immunity:

"We analyze the cholesterol atlas in the tumor microenvironment and find that intratumoral T cells have cholesterol deficiency, while immunosuppressive myeloid cells and tumor cells display cholesterol abundance. Low cholesterol levels inhibit T cell proliferation and cause autophagy-mediated apoptosis, particularly for cytotoxic T cells"

#Immunology #immunotherapy #immunooncology #CancerImmunity

https://www.sciencedirect.com/science/article/abs/pii/S1535610823001423?via%3Dihub

"To capture the complex interplay between the tumor antigenic landscape and anti-tumor immunity in lung cancer, we integrated genomics, transcriptomics, immunopeptidomics, spatial transcriptomics and multiplexed immunofluorescence (mIF) imaging to investigate the antigenic landscape in tumors with variable degrees of immune infiltration"
#Immunology #immunooncology

https://www.nature.com/articles/s43018-023-00548-5

'Our studies demonstrate that in vivo trans PD-L1/CD80 interactions do exist between T and tumor cells, and in vivo blockade of trans PD-L1/CD80 interactions or general PD-L1/CD80 interactions augment tumor immunity via expansion of IFN-γ-producing CD8+T cells and NOS2+macrophages in the tumor tissues.'

#immunology #immunooncology #immunotherapy #checkpointinhibitors

https://www.pnas.org/doi/10.1073/pnas.2205085120

Hunting submarines.

'Here, we report that CD8+T cells maintain the capacity to kill tumor cells that are entirely devoid of MHC-I expression. This capacity proves to be dependent on interactions between T cell NKG2D and tumor NKG2D ligands (NKG2DL).'
#Preprint #immunology #immunooncology #immunotherapy

https://www.biorxiv.org/content/10.1101/2023.02.02.526713v1

This makes sense - PD1/PDL1 are great targets, but the degree of dominance over the last decade was worrisome. Great to see more diversity

"Our current analysis of global IO clinical trials shows that the field took a turn in 2022 with respect to previous years. After more than a decade of an upward trajectory, we notice a decrease in new clinical trials, a shift driven largely by the reduction in phase II studies using anti-PD1/PDL1 mAbs."
#immunology #immunotherapy #immunooncology

https://www.nature.com/articles/d41573-023-00066-0

Then please consider joining our team to develop next-gen single-cell analysis methods and help advance the field of #precision #immunooncology

More info at https://drive.switch.ch/index.php/s/UDJYsEEpeHSCw2H

If you are interested don't hesitate to contact me by DM or email

Are you interested in the future of engineered immune cell therapies?

In this comprehensive review article in Science, Darrell Irvine (Massachusetts Institute of Technology) et al. discuss current progress in treating human disease with immune cell therapeutics, emerging strategies for immune cell engineering, and challenges facing the field: https://www.science.org/doi/10.1126/science.abq6990

#celltherapy #CART #cancer #tumor #immunooncology #immunotherapy

Went a little quiet on Science Twitter in 2022 during the long process of migrating alone in your 30s, and have now emerged into a brave new world. Here we go.

#introduction: I am an immunologist in biotech working on #autoimmune diseases and #immunooncology. Postdocced in #primaryimmunodeficiency, PhD in #cytokines. Fascinated by the power of the #immune response in all its spheres.

Hoping to follow other scientists, doctors and patients combating immune diseases here!

The best thing about being a #Pharmacometrician (IMHO) is that you never stop learning, and every job is different. Right now I work a lot in #Immunooncology, the use of monocolonal antibodies (#mAbs) for treating #Cancer. mAbs have their own interesting set of complexities. (Well, they're interesting after we've figured them out. Before that that they're just maddening.)